Ciprofloxacin pharmacokinetics in young cystic fibrosis patients after repeated oral doses

Therapie

Volumn 56, Issue 5, 2001, Pages 519-524

  Odoul, F ^a   Le Guellec, C ^a   Giraut, C ^a   De Gialluly, C ^a   Marchand, S ^a   Paintaud, G ^a   Saux, M C ^a   Rolland, J C ^a   Autret Leca, E ^a  

^a UNIVERSITÉ DE TOURS   (France)

Author keywords

Children; Ciprofloxacin; Cystic fibrosis; Pharmacokinetics

Indexed keywords

CIPROFLOXACIN;

ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CYSTIC FIBROSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG FORMULATION; FEMALE; GRAM NEGATIVE BACTERIUM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LUNG INFECTION; MALE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SCHOOL CHILD;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-INFECTIVE AGENTS; CHILD; CIPROFLOXACIN; CYSTIC FIBROSIS; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; PSEUDOMONAS INFECTIONS;

EID: 0035678935     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Pathogenesis of lung disease in cystic fibrosis
2. Microbiology of lung infection in cystic fibrosis patients
3. Clinical management of pulmonary disease in cystic fibrosis
4. Management of pulmonary disease in patient with cystic fibrosis
5. Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis: Current practice and suggestions for future directions
6. Pseudomonas infection in cystic fibrosis
7. Nebulised colimycin for early Pseudomonas colonisation in cystic fibrosis
8. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment
9. Ciprofloxacin as antipseudomonal treatment in patients with cystic fibrosis
10. Sequential ciprofloxacin therapy in pediatric cystic fibrosis: Comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations
11. Clinical pharmacokinetics of ciprofloxacin in patients with major burns
12. Pharmacokinetics and pharmacodynamics of fluoroquinolones
13. Ciprofloxacin in purulent exacerbations of chronic bronchitis: A clinical, microbiological and pharmacokinetic study
14. Penetration of ciprofloxacin and metabolites into human lung, bronchial and pleural tissue after 250 and 500 mg oral ciprofloxacin
15. Ciprofloxacin: An update review of its pharmacology, therapeutic efficacy and tolerability
16. Quinolone arthropathy in animals versus children
17. Fluoroquinolones in pediatrics
18. Fluoroquinolones in pediatrics
19. Rheumatologic aspects of pediatric cystic fibrosis patients treated with fluoroquinolones
20. Clinical use of fluoroquinolones in children
21. Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: Comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging
22. Oral ciprofloxacin in the treatment of paediatric cystic fibrosis: Clinical efficacy and safety evaluation using magnetic resonance image scanning
23. Ciprofloxacin in pediatrics: Worldwide clinical experience based on compassionate use-safety report
24. Drug disposition in cystic fibrosis
25. Optimisation of antibiotic therapy in cystic fibrosis patients: Pharmacokinetic considerations
26. Ciprofloxacin pharmacokinetics in patients with cystic fibrosis
27. Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients
28. Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients
29. Pharmacokinetics of ciprofloxacin in cystic fibrosis
30. Lack of unique ciprofloxacin pharmacokinetic characteristics in patients with cystic fibrosis
31. Enhanced ciprofloxacin clearance in cystic fibrosis patients
32. Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients
33. Pharmacokinetic studies of ciprofloxacin in children with cystic fibrosis
34. Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation
35. Pharmacokinetics of single-dose oral ciprofloxacin infants and small children
36. Single-dose and steady-state pharmacokinetics of a new oral suspension of ciprofloxacin in children
37. Apparent volume of distribution
38. Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin
39. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
40. Achieving an optimal outcome in treatment of infections: The role of clinical pharmacokinetics and pharmacodynamics of antimicrobials
41. Basis of anti-infective therapy: Pharmacokinetic-pharmacodynamic criteria and methodology for dual dosage individualisation
42. Mathematical examination of dual individualization principles (I): Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin
43. Multipledose ciprofloxacin kinetics in normal subjects
44. Principes de thérapeutique
45. Antibiotic dosing issues in lower respiratory tract infection: Population-derived area under inhibitory curve is predictive of efficacy
46. AUIC - The universal parameter within the constraint of a reasonable dosing interval